HUE073014T2 - Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén - Google Patents

Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén

Info

Publication number
HUE073014T2
HUE073014T2 HUE17158264A HUE17158264A HUE073014T2 HU E073014 T2 HUE073014 T2 HU E073014T2 HU E17158264 A HUE17158264 A HU E17158264A HU E17158264 A HUE17158264 A HU E17158264A HU E073014 T2 HUE073014 T2 HU E073014T2
Authority
HU
Hungary
Prior art keywords
safely
kidney disease
chronic kidney
effectively treating
secondary hyperparathyroidism
Prior art date
Application number
HUE17158264A
Other languages
English (en)
Hungarian (hu)
Inventor
Charles Bishop
Eric Messner
Original Assignee
Opko Renal Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Renal Llc filed Critical Opko Renal Llc
Publication of HUE073014T2 publication Critical patent/HUE073014T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE17158264A 2007-04-25 2008-04-25 Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén HUE073014T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91385007P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
HUE073014T2 true HUE073014T2 (hu) 2025-12-28

Family

ID=39926088

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17158264A HUE073014T2 (hu) 2007-04-25 2008-04-25 Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén

Country Status (12)

Country Link
US (3) US20100144684A1 (enExample)
EP (3) EP3225243B1 (enExample)
JP (5) JP2010525080A (enExample)
CA (1) CA2683514C (enExample)
DK (2) DK3335712T3 (enExample)
ES (2) ES3047207T3 (enExample)
FI (2) FI3225243T3 (enExample)
HU (1) HUE073014T2 (enExample)
PL (2) PL3335712T3 (enExample)
PT (2) PT3225243T (enExample)
SI (1) SI3225243T1 (enExample)
WO (1) WO2008134523A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
CA2640094C (en) 2006-02-03 2015-04-14 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
FI3225243T3 (fi) 2007-04-25 2025-10-13 Opko Renal Llc Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
CA2684778C (en) 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
SI2481400T1 (sl) 2007-04-25 2014-11-28 Opko IP Holdings II, Inc. Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 d 부족 및 결핍의 치료 방법
MX2010008894A (es) * 2008-02-13 2010-11-05 Dsm Ip Assets Bv Combinacion de vitamina d y 25-hidroxi-vitamina d3.
EP3112476B1 (en) 2008-04-02 2023-08-02 EirGen Pharma Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
US8518917B2 (en) * 2009-10-02 2013-08-27 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D analogs and their uses
EP3636280B1 (en) 2010-03-29 2025-05-14 EirGen Pharma Ltd. Methods and compositions for reducing parathyroid levels
TR201902517T4 (tr) * 2010-12-06 2019-03-21 Dsm Ip Assets Bv 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi.
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
MX2017001751A (es) * 2014-08-07 2017-05-30 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d.
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
WO2017117712A1 (zh) * 2016-01-05 2017-07-13 富士通株式会社 信息传输方法、装置和系统
SG10201913863TA (en) 2016-03-28 2020-03-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー, インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
JP7590184B2 (ja) 2018-04-03 2024-11-26 オプコ アイルランド グローバル ホールディングス リミテッド 肥満外科手術患者におけるカルシフェジオールの使用
EP3920938A1 (en) * 2019-02-06 2021-12-15 EirGen Pharma Ltd. Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
US20230293552A1 (en) * 2020-05-31 2023-09-21 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565924A (en) 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3833622A (en) 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US3880894A (en) 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS5832823A (ja) 1981-08-20 1983-02-25 Chugai Pharmaceut Co Ltd 脱癌剤
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja) 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンd↓3類組成物
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
EP0207638B1 (en) 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
JPS61293911A (ja) 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US5167965A (en) * 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JPH02240024A (ja) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンd↓3類製剤用組成物
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (ja) 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンd▲下3▼誘導体含有固形製剤組成物
JP2893140B2 (ja) 1990-11-30 1999-05-17 エスエス製薬株式会社 安定なビタミンd製剤
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンd3類軟カプセル剤の製造方法
DE69214704T2 (de) 1991-04-09 1997-04-17 Takeda Chemical Industries Ltd Stabilisiertes Vitamin D Arzneimittel
US5693615A (en) 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
ES2170069T3 (es) 1992-06-22 2002-08-01 Bone Care Int Inc 1-alfa-hidroxiprevitamina d para administracion oral.
US5354743A (en) 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en) 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6121469A (en) 1993-12-23 2000-09-19 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (ja) * 1994-03-02 1995-09-19 Teijin Ltd 二次性副甲状腺機能亢進症治療剤
IL110117A0 (en) 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
EP0769936A1 (en) 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
JPH0892098A (ja) 1994-09-27 1996-04-09 Teijin Ltd 肺結核治療剤
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US20020183288A1 (en) 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
WO1997011053A1 (en) 1995-09-21 1997-03-27 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
DE69716469T2 (de) * 1996-08-26 2003-02-20 Takeda Chemical Industries, Ltd. Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
EP0935523B1 (en) 1996-10-28 2004-09-29 Inc. General Mills Embedding and encapsulation of controlled release particles
JPH10158171A (ja) 1996-12-02 1998-06-16 Kita:Kk ビタミンd化合物を配合した眼内投与剤
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6034075A (en) 1997-03-20 2000-03-07 The Trustees Of Columbia University In The City Of New York Method of treating polycystic ovarian syndrome
JPH1175863A (ja) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd 25−ヒドロキシビタミンD3−1α−水酸化酵素および該酵素をコードするDNA
US20020076442A1 (en) 1997-09-02 2002-06-20 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
ATE515265T1 (de) 1998-03-27 2011-07-15 Univ Oregon Health & Science Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
EP1039882B1 (en) 1998-08-27 2010-11-10 Pfizer Health AB Therapeutic formulation for administering tolterodine with controlled release
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
WO2000018374A1 (en) 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
DK1119345T3 (da) 1998-10-09 2009-08-03 Gen Mills Inc Indkapsling af fölsomme flydende bestanddele i en matrix til opnåelse af adskilte opbevaringsstabile partikler
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
JP2000206312A (ja) * 1998-11-12 2000-07-28 Olympus Optical Co Ltd 光学素子
ATE260642T1 (de) 1998-12-17 2004-03-15 Alza Corp Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000059513A1 (en) 1999-04-01 2000-10-12 Johns Hopkins University NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3?
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
WO2000072831A1 (en) * 1999-05-27 2000-12-07 Drugtech Corporation Nutritional formulations
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
HK1046851A1 (en) 1999-08-31 2003-01-30 Chugai Seiyaku Kabushiki Kaisha Soft capsules
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
AU2001278956B2 (en) 2000-07-18 2007-04-05 Genzyme Corporation Stabilized 1alpha-hydroxy vitamin d
WO2002017848A1 (fr) 2000-08-29 2002-03-07 Nisshin Kasei Co., Ltd. Capsule en dur
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク,エス.エイ. ヒドロコドン放出制御製剤
US6479649B1 (en) 2000-12-13 2002-11-12 Fmc Corporation Production of carrageenan and carrageenan products
WO2002092056A1 (en) * 2001-05-15 2002-11-21 Warner-Lambert Company Llc Compaction process for manufacture of sodium phenytoin dosage form
EP1410794A1 (en) 2001-07-05 2004-04-21 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
US7033996B2 (en) 2001-08-31 2006-04-25 University Of Medicine & Dentistry Of New Jersey Method for the treatment of vitamin D related disease
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
CA2463505C (en) 2001-10-12 2011-07-12 Johns Hopkins University Low-calcemic oxime analogs of 1.alpha.,25-dihydroxy vitamin d3
US7056655B2 (en) * 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
EP1447082B1 (en) 2001-11-22 2010-11-10 Morishita Jintan Co., Ltd. Non-gelatinous capsules
EA008072B1 (ru) 2001-12-03 2007-02-27 Новацея, Инк. Фармацевтические составы, содержащие соединения активного витамина d
FR2829142B1 (fr) 2001-12-27 2004-02-13 Ulice Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NO20021592D0 (no) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
AU2003233735A1 (en) 2002-06-13 2003-12-31 Cytochroma Inc. 24-sulfoximine vitamin d3 compounds
ATE482694T1 (de) 2002-07-05 2010-10-15 Temrel Ltd Zusammensetzung zur kontrollierten wirkstoffabgabe
ATE373472T1 (de) * 2002-07-29 2007-10-15 Alza Corp Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
AU2002368245A1 (en) 2002-09-26 2004-04-19 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (ja) 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
JP2006514695A (ja) 2002-12-16 2006-05-11 テバ ファーマシューティカル インダストリーズ リミティド ビタミンd誘導体の前用量投与によってアレンドロネート又は他のビスフォスフォネートの全体利用効率を高める方法
DE602004015246D1 (de) * 2003-02-11 2008-09-04 Alza Corp Verfahren und dosierformen mit modifizierter schichtgeometrie
US7816341B2 (en) 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
EP1628620A4 (en) 2003-04-14 2010-01-06 Fmc Corp HOMOGENEOUS THERMOREVERSIBLES GEL WITH CARRAGEENAN REDUCED VISCOSITY AND PRODUCTS MANUFACTURED THEREOF
JP2006525367A (ja) * 2003-04-30 2006-11-09 ビオクセル エッセ ピ ア ジェミニビタミンd3化合物及びその使用方法
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
AU2004247272A1 (en) 2003-06-16 2004-12-23 Solx, Inc. Shunt for the treatment of glaucoma
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20050148557A1 (en) 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
AU2004275815A1 (en) * 2003-09-24 2005-04-07 Bioxell S.P.A. 1,3-diaclyated,26,27-alkyl/haloalkyl vitamin D3 compounds and methods of use thereof
US7053075B2 (en) 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
US9750797B2 (en) 2004-06-16 2017-09-05 Virbac Corporation Sustained release vaccine composition
US20050287213A1 (en) 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en) 2004-07-22 2006-01-26 David Boardman Process for preparing stabilized vitamin D
KR20070043806A (ko) 2004-07-29 2007-04-25 사노피-아벤티스 pH에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
AU2004325362B2 (en) 2004-12-03 2012-09-06 Council Of Scientific And Industrial Research Process of preparation of biodegradable films from semi refined kappa carrageenan
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
PL2985026T3 (pl) 2005-04-15 2023-02-20 Clarus Therapeutics, Inc. Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje
US20060257481A1 (en) 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US20080134937A1 (en) 2005-05-25 2008-06-12 Joo Hwan Yang Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (es) 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
DE602006006200D1 (de) 2005-09-29 2009-05-20 Roche Diagnostics Gmbh Antikörper gegen 25-hydroxyvitamin d
ITFI20050206A1 (it) 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
WO2007047327A2 (en) * 2005-10-12 2007-04-26 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
EP1959935A2 (en) 2005-10-26 2008-08-27 Banner Pharmacaps Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
CA2627351C (en) 2005-10-26 2012-05-01 Banner Pharmacaps, Inc. Lipophilic vehicle-based dual controlled release matrix system
AP2008004489A0 (en) 2005-11-01 2008-06-30 Cpkelco U S Inc Films and capsules made from modified carboxymethycellulose materials and methods of making same
WO2007068287A1 (en) 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
CA2640094C (en) 2006-02-03 2015-04-14 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
JP2009540053A (ja) 2006-06-06 2009-11-19 エフ エム シー コーポレーション カッパー−2カラギーナン組成物及びそれからつくられた製品
PL2679228T3 (pl) * 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
KR101170283B1 (ko) 2006-10-27 2012-07-31 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
US8501717B2 (en) 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
SI2481400T1 (sl) 2007-04-25 2014-11-28 Opko IP Holdings II, Inc. Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec
FI3225243T3 (fi) 2007-04-25 2025-10-13 Opko Renal Llc Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 d 부족 및 결핍의 치료 방법
DE102008006203B4 (de) * 2008-01-26 2011-03-17 Jost-Werke Gmbh Fahrzeugkupplung zum Herstellen einer mechanischen Verbindung zwischen einem ersten und einem zweiten Fahrzeug
MX2010008894A (es) 2008-02-13 2010-11-05 Dsm Ip Assets Bv Combinacion de vitamina d y 25-hidroxi-vitamina d3.
EP2249842B2 (en) 2008-02-13 2025-03-05 DSM IP Assets B.V. Use of 25-hydroxy-vitamin d3 and vitamin d to affect human muscle physiology
CA2731382C (en) 2008-07-24 2020-04-28 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
PL2341899T3 (pl) 2008-09-24 2015-05-29 Evonik Roehm Gmbh Opioidowa kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu z odpornością na działanie etanolu
JP5696149B2 (ja) 2009-09-10 2015-04-08 エフ エム シー コーポレーションFmc Corporation シームレスなアルギン酸塩カプセル
US8101203B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
US8101204B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
AU2010358565B2 (en) 2010-08-04 2016-07-14 R.P. Scherer Technologies, Llc Film-forming composition for soft capsules
TR201902517T4 (tr) 2010-12-06 2019-03-21 Dsm Ip Assets Bv 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi.
ES2614817T3 (es) 2010-12-28 2017-06-02 Future Diagnostics B.V. Reactivo de liberación para vitamina D
GB2502032B (en) 2011-03-02 2015-03-04 D3 Pharma Ltd Stable Vitamin D3 Composition
WO2012144789A2 (ko) 2011-04-20 2012-10-26 주식회사 서흥캅셀 붕해도 및 피막 경도를 개선한 비동물성 연질 캡슐 피막 조성물
CN102771688A (zh) 2011-05-13 2012-11-14 富曼实(上海)商贸有限公司 可食用液体填充的多糖胶囊
EP2815745A1 (en) 2013-06-21 2014-12-24 Swiss Caps Rechte und Lizenzen AG Soft shell capsule and process for its manufacture
CN103495176B (zh) 2013-10-26 2015-01-28 中山市凯博思淀粉材料科技有限公司 一种共混挤出法制备淀粉基软胶囊的方法
CN103520133B (zh) 2013-10-26 2015-02-04 中山市凯博思淀粉材料科技有限公司 一种淀粉基软胶囊的制备方法

Also Published As

Publication number Publication date
PT3335712T (pt) 2025-10-23
ES3047207T3 (en) 2025-12-03
DK3335712T3 (da) 2025-10-20
JP2014098034A (ja) 2014-05-29
PL3335712T3 (pl) 2025-12-22
PT3225243T (pt) 2025-10-01
EP3225243B1 (en) 2025-09-03
JP2010525080A (ja) 2010-07-22
FI3225243T3 (fi) 2025-10-13
EP2148683A1 (en) 2010-02-03
US11801253B2 (en) 2023-10-31
SI3225243T1 (sl) 2025-11-28
WO2008134523A1 (en) 2008-11-06
US20180021355A1 (en) 2018-01-25
EP2148683A4 (en) 2012-09-12
ES3044311T3 (en) 2025-11-26
DK3225243T3 (da) 2025-09-29
US20100144684A1 (en) 2010-06-10
EP3225243A1 (en) 2017-10-04
CA2683514A1 (en) 2008-11-06
JP2017075183A (ja) 2017-04-20
JP2018009040A (ja) 2018-01-18
FI3335712T3 (fi) 2025-10-23
EP3335712B1 (en) 2025-09-10
PL3225243T3 (pl) 2025-12-22
US20140274977A1 (en) 2014-09-18
JP2019196402A (ja) 2019-11-14
CA2683514C (en) 2019-07-09
EP3335712A1 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
PT3225243T (pt) Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica
ZA201003386B (en) Systems and methods for water treatment
PL2037936T3 (pl) Sposób leczenia i zapobiegania wtórnej nadczynności przytarczyc
EP1978807A4 (en) METHOD OF TREATING CHRONIC NEPHROPATHY
EP1999077A4 (en) SYSTEM AND METHOD FOR TREATING WASTEWATER
SG10201610076SA (en) Method and system for treating ballast water
EP2382010A4 (en) METHOD AND SYSTEMS FOR FAT REDUCTION AND / OR TREATMENT OF CELLULITE
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
EP2162399A4 (en) SYSTEM AND METHOD FOR WATER PROCESSING
ZA200805958B (en) Compositions and methods for preventing or treating feline chronic kidney disease
ZA201102035B (en) Methods and formulations for treating chronic liver disease
EP2170311A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
SI2520295T1 (sl) Postopki za preprečevanje in zdravljenje mukozitisa
IL184441A0 (en) Method and device for water treatment
ZA200701707B (en) Method of treating hyperphotaemia using lanthanum hydroxycarbonate
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
EP2114467A4 (en) BIOCIDAL COMPOSITION AND PROCESS FOR TREATING RECYCLED WATER SYSTEMS
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
ZA200808076B (en) Methods for preventing and treating amyloidogenic diseases
EP2143821A4 (en) DISCHARGE SURFACE TREATMENT METHOD AND REPAIR METHOD
EP2227439A4 (en) SYSTEM AND METHOD FOR STORAGE AND TREATMENT OF WASTEWATER
GB2459206B (en) Laminate and method of edge treatment therefor
ZA200902533B (en) Methods for treating and reducing the incidence of Newcastle disease
EP2043662A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASE